FDA grants second orphan drug designation to Hutchmed's sovleplenib, this time for AIHANov 5Regulatory milestoneHutchmedUpdated
HUTCHMED's Orpathys-Tagrisso filings for lung cancer accepted in Europe and JapanNov 2Clinical readoutAstraZenecaCardiff OncologyUpdated
HUTCHMED closes HMPL-A830 license deal with GSK for territories outside ChinaOct 21PartnershipHMPL-A830Hutchmed
HUTCHMED's HMPL-A830 trial registry posted, detailing 147-participant Phase I/IIa designOct 1Weekly roundup, 2 itemsHMPL-A830HutchmedUpdated
HUTCHMED, AstraZeneca file US NDA for Orpathys plus Tagrisso in MET-driven lung cancerSep 29Regulatory decisionAstraZenecaHutchmed
HUTCHMED details ESMO 2026 slots for SAFFRON, SANOVO Phase III lung cancer dataSep 24PublicationAstraZenecaHutchmed
HUTCHMED licenses HMPL-A830 to GSK; source cites both $1.295B and $1.185B totalsSep 3PartnershipHMPL-A830Hutchmed
HUTCHMED wins NMPA approval for ATLED in FGFR2-altered bile duct cancerAug 28Regulatory decisionHutchmed
HUTCHMED and AstraZeneca report positive Phase III SAFFRON data in EGFR-mutated lung cancerAug 17Clinical readoutAstraZenecaHutchmed
HUTCHMED posts H1 2026 revenue of $278.3M as China sales rebound and ATTC pipeline advancesJul 30Quarterly updateHutchmed
Hutchmed registers first-in-human Phase I/IIa trial of HMPL-A830 in solid tumorsJul 22Trial updateHMPL-A830Hutchmed
Hutchmed completes Phase 1 drug interaction study for HMPL-453 tartrate tabletsJul 13Trial updateHutchmed
HUTCHMED wins NMPA approval for Orpathys in MET-amplified gastric cancerJul 2Regulatory decisionAstraZenecaHutchmed